Related references
Note: Only part of the references are listed.Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma
Kotaro Hirashima et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Guidelines for the welfare and use of animals in cancer research
P. Workman et al.
BRITISH JOURNAL OF CANCER (2010)
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
Emmanuel S. Antonarakis et al.
CANCER LETTERS (2010)
mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
Guiqin Hou et al.
CANCER LETTERS (2010)
The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
Brigette B. Y. Ma et al.
INVESTIGATIONAL NEW DRUGS (2010)
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
C. A. Sparks et al.
ONCOGENE (2010)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer
Kenneth L. Scott et al.
NATURE (2009)
Common corruption of the mTOR signaling network in human tumors
S Menon et al.
ONCOGENE (2009)
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
R. Bianco et al.
BRITISH JOURNAL OF CANCER (2008)
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
Philipp C. Manegold et al.
CLINICAL CANCER RESEARCH (2008)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
Ahmad Awada et al.
EUROPEAN JOURNAL OF CANCER (2008)
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?
J. Boone et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Bradly G. Wouters et al.
NATURE REVIEWS CANCER (2008)
Phase I study of everolimus in pediatric patients with refractory solid tumors
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR
Guiqin Hou et al.
CANCER LETTERS (2007)
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma
Beata Herberger et al.
CLINICAL CANCER RESEARCH (2007)
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer
Bruce E. Johnson et al.
CLINICAL CANCER RESEARCH (2007)
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2007)
The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy
Robert T. Abraham et al.
CLINICAL CANCER RESEARCH (2007)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
Key cancer cell signal transduction pathways as therapeutic targets
RB Bianco et al.
EUROPEAN JOURNAL OF CANCER (2006)
Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer
SRD Johnston
CLINICAL CANCER RESEARCH (2006)
Therapeutic targets - MTOR and related pathways
Janet E. Dancey
CANCER BIOLOGY & THERAPY (2006)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
A Panwalkar et al.
CANCER (2004)
Lonidamine causes inhibition of anglogenesis-related endothelial cell functions
D Del Bufalo et al.
NEOPLASIA (2004)
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells
M Milella et al.
CLINICAL CANCER RESEARCH (2004)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
S Chan
BRITISH JOURNAL OF CANCER (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
Medical progress - Esophageal cancer
PC Enzinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo et al.
ONCOGENE (2000)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
